Quantcast

Latest Menorrhagia Stories

2008-09-02 21:00:05

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. today announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or...

2008-08-18 06:00:14

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that based on the robust efficacy demonstrated by Proellex(R) in the interim assessment of the Company's Phase II endometriosis study, there are sufficient patients currently enrolled to provide for adequate power calculations for the Phase III endometriosis trials. Because of the profound effect noted in this interim analysis, the Company has decided to curtail further patient recruitment for the study. Based on this decision, greater...

2008-08-05 09:01:31

NEWPORT, Ky., Aug. 5 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today positive top line results in two pivotal Phase 3 clinical trials of its proprietary investigational product, a modified-release (MR) formulation of tranexamic acid for the treatment of women with menorrhagia, or heavy menstrual bleeding, and its accompanying symptoms. "We are extremely pleased with the initial data from these pivotal trials and we look forward to continuing to work with the U.S. Food and...

2008-07-21 06:00:17

Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that the results of the initial Phase I/II clinical trial of Proellex(R) which was conducted in Europe are to be published in US Obstetrics and Gynecology Review in early August. In this study, women with fibroids were treated with Lucrin(R) (also known as Lupron(R)), one of three doses of Proellex, or placebo. Decreases in fibroid size were detected by ultrasound and there was a notable reduction in vaginal bleeding. The drug appeared...

2008-07-17 09:00:19

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is...

2008-07-16 18:00:12

Repros Therapeutics Inc. (NasdaqGM:RPRX) today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses after cessation of drug administration. As of this release, results from 13 women who had endometrial biopsies post menses following last dose of drug in a two-drug cycle extension study...

2008-07-10 09:01:29

WALTHAM, Mass., July 10 /PRNewswire/ -- According to Millennium Research Group's Global Markets for Hysterectomy Alternatives 2008 report, which covers global endometrial ablation (GEA) devices, uterine artery embolization (UAE) devices, hysteroscopes, and endometrial resection devices, the global hysterectomy market will generate more than $700 million in 2012, primarily driven by expanding GEA procedure volumes. In the US and UK, the availability of a sufficient level of reimbursement...

2008-07-01 21:00:05

By Anna Tong, The Lexington Herald-Leader, Ky. Jul. 1--A medical malpractice case in which an Owingsville woman accused a Lexington gynecologist of unnecessary castration -- removing her healthy ovaries -- without warning her of the surgery's consequences went to the jury Tuesday. The defense argued that the doctor used sound medical judgment. "He's done the worst thing a physician can do -- he violated her trust," said Lexington attorney, Sheila Hiestand. The plaintiff, 38 year-old...

ea090aef59365c1ace53d350a060ec061
2008-06-30 15:31:19

A new study from researchers at the University of Iowa has found that shortened times between menstrual periods may be an initial sign of menopause, while heavy bleeding seems to have other causes.  The researchers found that a shortened interval between periods, fewer than 21 days, in women aged 42 to 52 indicated the women were in the early stages of menopause. These periods were often "anovulatory", meaning the women did not ovulate even though they experienced bleeding. The...

2008-06-24 18:01:16

By Anna Tong, The Lexington Herald-Leader, Ky. Jun. 24--Attorneys delivered opening statements Tuesday in a malpractice trial involving one of six women who accused a Lexington obstetrician and gynecologist of unnecessarily removing their ovaries. The lawsuit, originally filed in 2003, claims that Dr. Michael Guiler performed medically unnecessary oophorectomies, needlessly leaving the women at risk for breast cancer, embolisms and dementia because they can no longer produce their own...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related